NT-3 Levels and Function in Individuals With CMT

Launched by ZARIFE SAHENK · Aug 17, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating a substance called NT-3 in people with Charcot-Marie-Tooth Disease (CMT) and other types of nerve damage known as peripheral neuropathy. The researchers want to find out how NT-3 levels in the blood relate to how well participants function in their daily lives. By understanding this connection, the study aims to improve knowledge about these conditions and potentially help develop better treatments in the future.

To participate in the trial, individuals must be at least 7 years old and have a confirmed diagnosis of peripheral neuropathy or CMT. Participants should be able to complete certain assessments and attend scheduled appointments. However, those who are currently pregnant or have specific health issues that might affect their safety or the study's results will not be eligible. If you join the trial, you can expect to have your blood tested for NT-3 levels and to undergo evaluations to help the researchers learn more about your condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Males or females from 7 years of age or older
• • Diagnosis of acquired peripheral neuropathy (PN) such as due to diabetes, chemo-induced, autoimmune chronic inflammatory demyelinating polyneuropathy (CIDP) established by a report of electrical studies or with a known genetic CMT diagnosis. Definitive diagnosis of PN is established with a report of electrical studies, EMG/nerve conduction studies.2
• • Perform assessments to the best of their ability with reliable results as deemed by the evaluator.
• • Ability to attend scheduled appointments
• • Ability to provide informed consent (or assent for ages 9-18)
• Exclusion Criteria:
• • Current pregnancy per medical history
• • Has a medical condition or extenuating circumstances that, in the opinion of the investigator, might compromise the subject's wellbeing, safety, or clinical interpretability